Praveen Dayalu
Professor of Neurology
Medical Director
Taubman Neurology
Neurology
1500 E. Medical Center Drive, 1914 Taubman Center
Ann Arbor, MI 48109-5316
[email protected]

Available to mentor

Praveen Dayalu
Clinical Professor
  • Recent Publications
  • Recent Publications See All Publications
    • Journal Article
      Publisher Correction: Pepinemab antibody blockade of SEMA4D in early Huntington's disease: a randomized, placebo-controlled, phase 2 trial.
      Feigin A, Evans EE, Fisher TL, Leonard JE, Smith ES, Reader A, Mishra V, Manber R, Walters KA, Kowarski L, Oakes D, Siemers E, Kieburtz KD, Zauderer M, Huntington Study Group SIGNAL investigators . Nat Med, 2024 Feb; 30 (2): 606 DOI:10.1038/s41591-022-02070-0
      PMID: 36195687
    • Journal Article
      Safety and efficacy of valbenazine for the treatment of chorea associated with Huntington's disease (KINECT-HD): a phase 3, randomised, double-blind, placebo-controlled trial.
      Furr Stimming E, Claassen DO, Kayson E, Goldstein J, Mehanna R, Zhang H, Liang GS, Haubenberger D, Huntington Study Group KINECT-HD Collaborators . Lancet Neurol, 2023 Jun; 22 (6): 494 - 504. DOI:10.1016/S1474-4422(23)00127-8
      PMID: 37210099
    • Journal Article
      Advance Care Planning and Health-Related Quality of Life in Huntington Disease: Results from a Multicenter National Study.
      Sokol LL, Troost JP, Bega D, Kluger BM, Prigerson HG, Nance M, Frank S, Perlmutter JS, Dayalu P, Cella D, Carlozzi NE. Palliat Med Rep, 2023 4 (1): 79 - 88. DOI:10.1089/pmr.2022.0034
      PMID: 36969738
    • Journal Article
      Pepinemab antibody blockade of SEMA4D in early Huntington's disease: a randomized, placebo-controlled, phase 2 trial.
      Feigin A, Evans EE, Fisher TL, Leonard JE, Smith ES, Reader A, Mishra V, Manber R, Walters KA, Kowarski L, Oakes D, Siemers E, Kieburtz KD, Zauderer M, Huntington Study Group SIGNAL investigators . Nat Med, 2022 Oct; 28 (10): 2183 - 2193. DOI:10.1038/s41591-022-01919-8
      PMID: 35941373
    • Journal Article
      Serotonin Transporter Imaging in Multiple System Atrophy and Parkinson's Disease.
      Chou KL, Dayalu P, Koeppe RA, Gilman S, Spears CC, Albin RL, Kotagal V. Mov Disord, 2022 Nov; 37 (11): 2301 - 2307. DOI:10.1002/mds.29220
      PMID: 36102173
    • Proceeding / Abstract / Poster
      J05 Interim results from cohort 1 of the double-blind, dose-escalation phase I/II clinical trial of amt-130 (HD-genetrx-1) for early-stage huntington’s disease (HD)
      Furr Stimming E, Sung V, Testa C, Kostyk S, Ross CA, Samii A, Geschwind MD, Hall D, Dayalu P, Lonser R, Elder B, Larson PS, Cooper DL, Clarkin M, Ali TM, Dolmetsch RE. 2022 Sep; a95 - a95. DOI:10.1136/jnnp-2022-ehdn.255
    • Preprint
      Articulatory Coordination for Speech Motor Tracking in Huntington Disease
      Perez M, Romana A, Roberts A, Carlozzi N, Miner JA, Dayalu P, Provost EM. 2021 Sep 28; arXiv, DOI:10.48550/arxiv.2109.13815
    • Journal Article
      Donor-containing cortical and intraventricular glioneuronal nodules in Huntington's disease brain decades after fetal cell transplantation.
      Pinarbasi ES, Liu EA, Yu Z, Kopyov O, Brown NA, Dayalu P, Lieberman AP. Acta Neuropathol, 2021 Jun; 141 (6): 979 - 981. DOI:10.1007/s00401-021-02292-5
      PMID: 33683397